



## Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m. E.T. on Wednesday, February 25, 2026 at the Oppenheimer 36<sup>th</sup> Annual Healthcare Life Sciences Conference.

A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at [www.q32bio.com](http://www.q32bio.com). Archived replays will be available for 90 days following the event.

### About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata<sup>1</sup>, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R $\alpha$  antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit [www.Q32Bio.com](http://www.Q32Bio.com).

<sup>1</sup>National Alopecia Areata Foundation

### Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website [www.Q32Bio.com](http://www.Q32Bio.com), including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

### Contacts:

Investors: Brendan Burns  
Argot Partners  
212.600.1902  
[Q32Bio@argotpartners.com](mailto:Q32Bio@argotpartners.com)

Media: David Rosen  
Argot Partners  
646.461.6387  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-302689781.html>

SOURCE Q32 Bio